Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00190606 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of Duloxetine, Placebo and Pelvic Floor Muscle Training in Subjects With Stress Urinary Incontinence
A Phase 2 study of Urinary Stress Incontinence, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 200
- Enrollment target
- 2
- Study locations
NCT00190606 is a Phase 2 study of Urinary Stress Incontinence that has completed, run by Eli Lilly and Company. The registered enrollment target is 200 participants. The trial reports 2 study locations across 2 states.
The verdict
NCT00190606, a Phase 2 study of Urinary Stress Incontinence, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 200 participants
- Enrollment target
- 2
- Study locations
Study Summary
The study is a comparison of the efficacy and safety of duloxetine and pelvic floor muscle training with that of placebo in patients with moderate to severe stress urinary incontinence
Conditions Studied
Interventions
- DRUG Duloxetine
- DRUG placebo
- PROCEDURE Pelvic Floor Muscle Training (PFMT)
- PROCEDURE Imitation PFMT
Study Locations (2)
Florida
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday - Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician - Weston
Other
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday - Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician - Nieuwegein
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2002-01 |
| Est. Completion | 2006-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00190606
The ClinicalTrials.gov registry entry for NCT00190606 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Urinary Stress Incontinence appearing as the primary indexed condition, and to 4 interventions - of which Duloxetine is the first listed.
NCT00190606 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Florida, Other.
Frequently Asked Questions
What is clinical trial NCT00190606 about?
NCT00190606 is a clinical study titled "Efficacy and Safety of Duloxetine, Placebo and Pelvic Floor Muscle Training in Subjects With Stress Urinary Incontinence". The study is a comparison of the efficacy and safety of duloxetine and pelvic floor muscle training with that of placebo in patients with moderate to severe stress urinary incontinence
What is the current status of trial NCT00190606?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 200 participants. The study started on 2002-01. Estimated completion is 2006-04.
What conditions does trial NCT00190606 study?
This clinical trial studies the following conditions: Urinary Stress Incontinence.
What interventions are being tested in trial NCT00190606?
The interventions under investigation include: Duloxetine (DRUG), placebo (DRUG), Pelvic Floor Muscle Training (PFMT) (PROCEDURE), Imitation PFMT (PROCEDURE).
Who is sponsoring clinical trial NCT00190606?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00190606 being conducted?
This trial has 2 study locations across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.